BXT-25: A New Solution for Late Stage Treatment of Wuhan Coronavirus

February 13, 2020

On January 31st, 2020, the WHO (World Health Organization) officially declared the novel coronavirus outbreak (2019-nCoV) a global health emergency. First discovered in the Chinese city of Wuhan, the 2019-nCoV has now spread to 25 countries around the globe, with an estimated 40,655 cases and 910 deaths. Despite continued efforts, there are currently still no vaccines to prevent 2019-nCoV infection nor are there specific anti-viral treatments recommended for 2019-nCoV infection.

Of those patients that progress to late-stage 2019-nCoV, the majority experience acute respiratory distress syndrome (ARDS), also known as severe respiratory distress syndrome (SRDS), the leading cause of death in 2019-nCoV patients. ARDS is a progressive disease characterized by low blood oxygen levels due to buildup of fluids in the tiny airsacs of the lungs known as alveoli. The primary treatment for ARDS is oxygen therapy coupled with ventilator support. Sometimes diuretics are used to increase urination and control fluid build-up in the lungs. In extreme cases, extracorporeal membrane oxygenation (ECMO) is used---a machine that pumps blood from the patient’s body to an artificial lung (oxygenator) that adds oxygen to it and removes carbon dioxide.

Bioxytran Inc., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the lungs, brain, heart, and other vital organs offers a new and possibly life-saving treatment option for late-stage 2019-nCoV.

Bioxytran’s leading drug candidate BXT-25, a glycol-polymer made of hybrid molecules of HEME chemical structure and a proprietary polymer chemical structure, is designed to carry oxygen to areas of the body where blood flow is blocked. Engineered to be 1/5000 the size of red blood cells and administered intravenously, BXT-25 binds to oxygen molecules as blood passes through the lungs and carries oxygen effectively to all the body’s vital organs. As long as vital organs continue to receive oxygen, the patient can survive long enough for the body’s immune system to kill the virus.

“In situations like this pandemic where resources are stretched to their limits, we are looking to develop a common-sense solution to improve the mortality rate of this disease right away” says CEO David Platt of Bioxytran Inc., who believes BXT-25 will be a breakthrough in treatment of 2019-nCoV. “BXT-25 represents a way to deliver oxygen to tissue without the intervention of the alveoli” explains Dr. Juan Carlos Lopez-Talavara, Bioxytran’s Medical Advisor. “We believe the molecule will diffuse into and out of the fluid in the alveoli in order to achieve oxygenation…and is not expected to have any side effects.”

While the world waits for a vaccine to be developed and newer and better treatment options to surface, the death toll of 2019-nCOV rises steadily from ARDS. We can sit back and be oblivious, or we can be proactive and spread the news of promising treatments so that we are better prepared in the case this disease reaches our borders. Please share this article with your colleagues, friends and family! For more information on Bioxytran Inc. Please download our Company Presentation - https://bit.ly/3bAX9Yv

References:

    1.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/index.html
    2.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/about/transmission.html
    3.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/faq.html
    4.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/about/symptoms.html
    5.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/summary.html#anchor_1580079137454
    6.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
    7.      Novel Coronavirus 2019, Wuhan, China. (2020, January 30). Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html